Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients

Affiliations

¹ Curry International Tuberculosis Centre, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA john.metcalfe@ucsf.edu.
² Biomedical Research and Training Institute, Harare, Zimbabwe.
³ Curry International Tuberculosis Centre, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.
⁴ National Tuberculosis Control Program, Harare, Zimbabwe.
⁵ Harare City Health Department, Harare, Zimbabwe.
⁶ Biomedical Research and Training Institute, Harare, Zimbabwe University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.

John Z Metcalfe et al. Eur Respir J. 2015 May.

. 2015 May;45(5):1504-6.

doi: 10.1183/09031936.00214114. Epub 2015 Mar 18.

¹ Curry International Tuberculosis Centre, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA john.metcalfe@ucsf.edu.
² Biomedical Research and Training Institute, Harare, Zimbabwe.
³ Curry International Tuberculosis Centre, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.
⁴ National Tuberculosis Control Program, Harare, Zimbabwe.
⁵ Harare City Health Department, Harare, Zimbabwe.
⁶ Biomedical Research and Training Institute, Harare, Zimbabwe University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.

No abstract available

References

1. World Health Organization. Global Tuberculosis Report 2014. Accessed at http://www.who.int/tb/publications/global_report/en/ on November 19, 2014.
1. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J. 2013 Jul;42(1):252–71. - PubMed
1. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J. 2013 Sep;42(3):708–20. - PubMed
1. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane database of systematic reviews. 2014;1:CD009593. - PMC - PubMed
1. Kennedy N, Gillespie SH, Saruni AO, et al. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. The Journal of infectious diseases. 1994 Sep;170(3):713–6. - PubMed